Latest Nasdaq News

Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.

Ovanti Limited announces a strategic leadership change in its US operations to boost its BNPL platform Flote’s commercialisation and prepare for a potential NASDAQ listing via SPAC.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Tungsten Mining is pursuing a US stock exchange listing to tap into deeper capital markets and strengthen ties with US government and industry stakeholders, complementing its existing ASX listing.

Aurora Energy Metals has completed the sale of its Aurora Uranium Project to Eagle Nuclear Energy, receiving A$24.2 million in equity and retaining future milestone-linked payments and royalties.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Elevra Lithium Limited reported an 8% revenue increase and a US$74 million profit for the first half of FY26, driven by higher lithium prices and strategic merger synergies. The company advances its North American Lithium expansion while managing temporary production challenges.

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Global X Management (AUS) Limited has announced estimated distributions for three ETFs listed on the ASX AQUA Market for the period ending 28 February 2026, providing key dates and dividend reinvestment plan eligibility.

American West Metals has appointed a top Washington DC advisory firm to deepen US government engagement for its West Desert Project, aiming to establish the first domestic indium supply chain amid critical minerals supply risks.